Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma
https://link.springer.com/article/10.1186/s12943-023-01886-9 Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies...